| Title |
Immunotherapy for breast cancer: past, present, and future
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, December 2016
|
| DOI | 10.1007/s10555-016-9654-9 |
| Pubmed ID | |
| Authors |
Alison Spellman, Shou-Ching Tang |
| Abstract |
Immunotherapy has shown promise in many solid tumors including melanoma and non-small cell lung cancer with an evolving role in breast cancer. Immunotherapy encompasses a wide range of therapies including immune checkpoint inhibition, monoclonal antibodies, bispecific antibodies, vaccinations, antibody-drug conjugates, and identifying other emerging interventions targeting the tumor microenvironment. Increasing efficacy of these treatments in breast cancer patients requires identification of better biomarkers to guide patient selection; recognizing when to initiate these therapies in multi-modality treatment plans; establishing novel assays to monitor immune-mediated responses; and creating combined systemic therapy options incorporating conventional treatments such as chemotherapy and endocrine therapy. This review will focus on the current role and future directions of many of these immunotherapies in breast cancer, as well as highlighting clinical trials that are investigating several of these active issues. |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 1% |
| Unknown | 75 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 21% |
| Student > Bachelor | 13 | 17% |
| Student > Ph. D. Student | 9 | 12% |
| Student > Master | 5 | 7% |
| Other | 5 | 7% |
| Other | 8 | 11% |
| Unknown | 20 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 19 | 25% |
| Medicine and Dentistry | 13 | 17% |
| Agricultural and Biological Sciences | 11 | 14% |
| Immunology and Microbiology | 3 | 4% |
| Psychology | 3 | 4% |
| Other | 6 | 8% |
| Unknown | 21 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 December 2016.
All research outputs
#20,363,191
of 22,912,409 outputs
Outputs from Cancer and Metastasis Reviews
#736
of 810 outputs
Outputs of similar age
#349,822
of 415,658 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#9
of 9 outputs
Altmetric has tracked 22,912,409 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 810 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 415,658 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.